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(1). Projections show that the prevalence of HF will increase 
46% from 2012 to 2030, resulting in >8 million adults with 
HF (2). In 2012, the total cost for HF was estimated to be 
$30.7 billion. Of this total, 68% was attributable to direct 
medical costs related to hospitalizations (2). Projections show 
that by 2020, the total cost of HF will increase almost 127% to 
$69.7 billion from 2012 (2).
Left ventricular assist devices (LVADs) are a novel 
strategy for HF treatment, whereby the heart is provided 
with  sufficient mechanical circulatory support to allow for 
offloading, which in turn promotes myocardial remodel-
ing and recovery (3-5). The first-generation pulsatile flow 
devices have been replaced by newer generation continu-
ous-flow LVADs that are smaller and more durable (6). In 
 particular, LVADs, which can be implanted minimally in-
vasively without sternotomy or cardiopulmonary bypass, 
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Introduction
Heart failure (HF) is a highly significant medical and eco-
nomic problem afflicting an estimated 5.7 million Americans 
ABSTRACT
Purpose: Heart failure is a worldwide epidemic that is unlikely to change as the population ages and life expectan-
cy increases. We sought to detail significant recent improvements to the Dassault Systèmes Living Heart Model 
(LHM) and use the LHM to compute left ventricular (LV) and right ventricular (RV) myofiber stress distributions 
under the following 4 conditions: (1) normal cardiac function; (2) acute left heart failure (ALHF); (3) ALHF treated 
using an LV assist device (LVAD) flow rate of 2 L/min; and (4) ALHF treated using an LVAD flow rate of 4.5 L/min.
Methods and Results: Incorporating improved systolic myocardial material properties in the LHM resulted in its 
ability to simulate the Frank-Starling law of the heart. We decreased myocardial contractility in the LV myocar-
dium so that LV ejection fraction decreased from 56% to 28%. This caused mean LV end diastolic (ED) stress to 
increase to 508% of normal, mean LV end systolic (ES) stress to increase to 113% of normal, mean RV ED stress to 
decrease to 94% of normal and RV ES to increase to 570% of normal. When ALHF in the model was treated with 
an LVAD flow rate of 4.5 L/min, most stress results normalized. Mean LV ED stress became 85% of normal, mean 
LV ES stress became 109% of normal and mean RV ED stress became 95% of normal. However, mean RV ES stress 
improved less dramatically (to 342% of normal values).
Conclusions: These simulations strongly suggest that an LVAD is effective in normalizing LV stresses but not RV 
stresses that become elevated as a result of ALHF.
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 remove some of the large risks  associated with major sur-
gery (7). These devices can deliver a range of flow output 
between 2-10 L/min (8), depending on the level of support 
needed. These improvements in device technology, coupled 
with greater clinical expertise surrounding LVADs, led to a 
decrease in patient risk over the last decade, making LVAD 
treatment an increasingly viable option for many patients 
(9). Furthermore, roughly 5% of LVAD-treated patients ex-
perience a full recovery, allowing for reduced support and, 
in some cases, device explantation (10, 11). Recent results 
show that miniaturized, less invasive, partial-support devic-
es operating at low flow rates may have the potential to be 
used in more patients, particularly those with INTERMACS 
classification 4 and greater (12, 13).
Although clinical expertise regarding LVADs is increasing, 
the exact mechanisms responsible for myocardial recovery 
and reversal of HF are still not fully understood, limiting the 
ability to predict long-term function, durable recovery or re-
mission of HF (10, 14). Computational studies have already 
been identified as a means to accelerate successful LVAD 
design and treatment protocols due to the inherent ability 
of cheaply and efficiently perturbing treatment parameters 
(15). Additionally, realistic computational models provide a 
wealth of information for clinical decision making (16), and 
may elucidate mechanical cues responsible for recovery that 
are otherwise unobtainable.
In this novel computational study concerned with the 
normal human heart, acute left HF, and LVAD therapy, we 
sought to detail significant improvements in the systolic 
material properties of the Dassault Systèmes Living Heart 
Model (LHM) and use it to compute left and right ventricu-
lar myofiber stress distributions under the following 4 con-
ditions: (1) normal cardiac function; (2) acute left HF with 
an LV ejection fraction (EF) of 28%; (3) acute left HF using 
an LVAD flow rate of 2 L/min; and (4) acute left HF treated 
using an LVAD flow rate of 4.5 L/min. Relatively few com-
putational studies have investigated the effect of LVADs on 
cardiac function utilizing realistic geometries (17, 18) due to 
the complexities involved, and to the best of our knowledge, 
our study is the first to present stress and strain results in 
both ventricles.
Methods
Whole heart modeling of the normal human heart
Baillargeon et al (19) created a finite element model of 
the whole heart on the basis of the existing solid model il-
lustrated in Figure 1A. This made it possible to model all 
4 chambers as electrically excitable, deformable, hyperelastic, 
electroactive bodies connected via in-flow and out-flow con-
ditions of viscous resistance type (19). We refer the interested 
reader to Baillargeon et al (19) for the full description of the 
model, including the continuum model of electro- mechanical 
coupling, the balance equations, and the constitutive equa-
tions. Here we only present the changes in the LHM that were 
pertinent to this study.
The passive material response of the cardiac tissue uses 
an anisotropic hyperelastic formulation based on that pro-
posed by Holzapfel and Ogden (20). In the LHM, this response 
appears to be more stable than the Fung response (21). The 
deviatoric and volumetric responses are governed by the 
strain energy potentials in Equations [1 and 2], with param-
eters defined in Table I.
 
Ψdev
b I i
i
b I fs
fsi f s
b Ia
b
e
a
b
e
a
b
ei i fs= + −{ }+− −
=
∑2 2 1 2
1 4
2
83 1( ) ( )
,
( fs )
2
1−{ }  
Eq. [1]
 Ψ =
−
−





D
J
J
1 1
2
ln( ) .
vol
2
 Eq. [2]
The passive model parameters used in our study follow 
from the revised parameters presented in Baillargeon et al 
(22), which improved the LHM’s performance in line with phys-
iological expectations. This material model, Equations [1 and 
2], ensures that the material exhibits the well-documented 
exponential and anisotropic response to strain (23-25) while 
enforcing near incompressibility.
Fig. 1 - (A) Solid model of the human heart 
used as the basis for our improved model. 
It was created from computed tomography 
and magnetic resonance imaging; adapted 
with permission from (Zygote Media Group 
and Inc., 2014). (B) Mechanical finite ele-
ment model of the human heart discretized 
with 449,560 linear tetrahedral elements, 
12,915 linear quadrilateral shells, 7577 lin-
ear triangular shells, 636 linear truss ele-
ments, 16,824 rigid triangular elements, 
130,290 nodes, and 443,564 mechanical 
degrees of freedom. (C) Electrical finite ele-
ment model of the human heart discretized 
with 449,560 linear tetrahedral elements, 
655 1D linear conduction elements (red), 
103,770 nodes, and 103,770 electrical de-
grees of freedom. (D) Fiber orientations of 
the Living Heart Model.
Sack et al  423
© 2016 The Authors. Published by Wichtig Publishing
Improvements to the Living Heart Model
This study incorporates recent improvements to the 
active-tissue material model, intended to capture the 
 Frank-Starling effect (i.e., the strength of the heart’s systolic 
contraction is directly proportional to its diastolic expansion). 
The active tissue response now contains length-dependent 
considerations of regional sarcomere lengths when the active 
response is determined. This affects the stress components in 
the fiber and sheet directions in the constitutive model.
The active stress in the cardiac muscle fiber direction is 
now defined by the following time-varying elastance model 
(26): 
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with parameters as defined in Table I. The mathemati-
cal description of active tension, Equations [3-7], ensures a 
smooth yet steep transition from zero to peak active tension 
at time t0 and then a smooth decline back to zero for the 
specified relaxation time tr.
As in previous work (19), the total stress in the fiber di-
rection, σf , is equal to the active stress, σaf , plus the passive 
stress, σpf :
 σ σ σf pf af= +  Eq. [8]
Total stress in the sheet direction, σs, is the sum of the 
passive stress, σps, and a fraction of the stress in the fiber di-
rection, nσaf (where n is a scalar value less than 1.0 and rep-
resents the interaction between the adjacent muscle fibers):
 σ σ σs ps afn= +  Eq. [9]
The value of n affects not only the total contractility of 
the chambers, but also the degree of twist developed in the 
chamber during the cardiac cycle. The magnitude of contrac-
tility for each chamber was tuned to provide the appropriate 
EF for that chamber. This involved tuning Tmax , n (to limit the 
twist of the LV and RV) and l0.
Figure 1B shows the mechanical finite-element model of 
Zygote’s second-generation solid heart geometry, which is dis-
cretized with more than 480,000 mixed elements, resulting in 
130,290 nodes and 443,564 mechanical degrees of freedom. 
Figure 1C illustrates the electrical finite- element model, high-
lighting the representative Purkinje fiber network, discretized 
by over 600 1D linear conduction elements embedded in the 
same mesh for the ventricles and atria as the mechanical 
model. The muscle fiber model, shown in Figure 1D, is pre-
scribed to all solid elements in the model.
Living Heart Model with simulated acute left heart failure
Systolic heart failure due to left ventricular dysfunc-
tion refers to the severely impaired heart function that re-
sults from reduced LV contractility. Loss of systolic function 
causes reduced ventricular emptying, resulting in increased 
TABLE I -  Constitutive parameters for the passive and active mate-
rial response
Passive  
Parameters
Description
a,b Governs the isotropic response of the tissue
af ,bf Governs additional stiffness in the fiber direction
as,bs Governs additional stiffness in the sheet direction
afs,bfs Governs coupling stiffness in the fiber and sheet di-
rections
I1 The first deviatoric strain invariant
I4i A pseudo-invariant defined as Ai∙C ∙ Ai
I8fs A pseudo-invariant defined as Af∙C ∙ As
C The Right Cauchy-Green tensor
Ai Vector in direction i
D Multiple of Bulk modulus (K = 2/D)
J The third deformation gradient invariant
Active  
Parameters
Description
Tmax Constitutive law contractility scaling factor (value 
directly scales ejection fraction)
Ca0 The peak intercellular calcium concentration
Ca0max The maximum intercellular calcium concentration
B Governs the shape of the peak isometric tension-
sarcomere length relation
l0 The sarcomere length below which no active force 
develops
t0 Time to reach peak tension
m,b Coefficients that govern the shape of the linear re-
laxation duration and sarcomere length relaxation
E
ff
Lagrangian Strain tensor component aligned with 
the local muscle fiber direction
lr The initial sarcomere length
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LV  end-diastolic (ED) volume and pressure. This acute left 
heart failure (ALHF) is the pathological condition simulated 
in this study. The loss of contractility was simulated by the 
single adjustment of parameter Tmax in the LV until an EF 
symptomatic of HF was produced in the LHM. This simula-
tion resulted in an EF of 28% with a value of Tmax at 25% of its 
normal value. Healthy values for EF are set at values >50%, 
with 35-50% representing a “grey area” for clinical diagnosis 
and values <35% clearly indicative of HF (27, 28). Average 
EF measurements of patients enrolled in larger trials report 
even lower values ranging from 27% to 34% (29, 30), placing 
our simulated ALHF model as a prominent dysfunction well 
away from “grey area” values.
In silico simulation of LVAD in the acutely failing human heart
By considering the newer-generation continuous flow de-
vices, whereby the small size of the LVAD allows for minimally 
invasive attachment, only the effect of the device is simulated, 
i.e., the flow conditions between the cavities are modified to 
simulate differing LVAD support. The LVAD inflow cannula tip 
is inserted into the LV, and the outflow, connecting the device 
to the arterial network, is usually attached via the aorta. The 
acutely failing human heart model described above was further 
modified to simulate the effect of the LVAD through the intro-
duction of an additional fluid exchange between the beating 
LV fluid cavity and the arterial system. The circulatory system 
included lumped compliance and resistance parameters rep-
resenting the viscous fluid exchanges amongst the 4-chamber 
heart, the arterial system, the pulmonary system, and the ma-
jor linking vasculature. A schematic diagram outlining the fluid 
connections between the electro-mechanically driven heart 
and the lumped circulatory system with the LVAD is presented 
in Figure 2. The LVAD has an additive contribution to the arterial 
system that provides a constant blood flow that complements 
the LV ejection output while reducing LV physical diastolic load-
ing. In these simulations, output from the LVAD was set at 2.0 L/
min and again at 4.5 L/min, indicative of the range of realistic 
output from the miniaturized newer-generation LVADs (8, 12). 
Aside from the LVAD, all other fluid exchanges are pressure- 
driven by the realistic mechanical model of the 4-chamber heart.
Because the LVAD resides outside the heart and is surgi-
cally connected to the LV via a small inflow cannula, the re-
straint on LV motion is considered negligible and is ignored 
in the model set up. To restrict rigid body motion, Dirichlet 
boundary conditions are applied to the truncated branches 
stemming off of the aortic arch (see Fig. 2). The geometric 
representations of the aorta, pulmonary trunk, and vena ca-
vae are bypassed by the lumped blood-flow model and are 
connected passively to the model purely as a means to en-
force realistic boundary conditions.
Results
The LHM simulated heart function within the range for 
healthy human adults; functional parameters are presented 
in Table II.
The effects of reduced contractility in the LV cause dra-
matic changes throughout the cardiovascular system. The 
LV experiencing ALHF undergoes volumetric overloading 
throughout the cycle, which results in a significant eleva-
tion in diastolic pressures. Specifically, there were increases 
in the ED volume of 35% and the ED pressure of 159%. This 
increased cavity volume of the acutely failing LV throughout 
the cardiac cycle results in a sustained state of elongation for 
the cardiac tissue throughout the cycle. In addition, the de-
pendence of RV mechanics on healthy LV function is made 
clear by the degree of impairment the RV experiences. Both 
diastolic and systolic RV function is significantly compromised 
by the enlarged LV.
The introduction of the LVAD changes the hemodynamic 
state of the entire cardiovascular system. The additional flow 
conditions simultaneously reduce the diastolic loading of 
the LV and increase the arterial pressure, establishing a new 
equilibrium that generates more positive cardiac outcomes 
throughout the heart. As the flow rate of the device  increases, 
the reduced loading shifts the ED state of the failing LV towards 
normal values. As LVAD flow increases, the LV PV-loop becomes 
more triangular, indicative of the device’s effect during the nor-
mally isovolumetric periods of the  cardiac cycle (31, 32).
Stroke volume (SV) and EF quantified from the ED and end-
systolic (ES) volumes alone significantly misrepresent the total 
LV output by neglecting the volume contribution of the device 
Fig. 2 - Schematic of the electromechanical model coupled with the 
circulatory system and LVAD. The truncated branched arteries from 
the aortic arch are fixed to prevent rigid body motion. R
MV
 is mi-
tral valve resistance, R
AO
 is aortic valve resistance, C
ART
 is systemic 
arterial compliance, R
ART
 is systemic arterial resistance, C
VEN
 is ve-
nous compliance, R
VEN
 is venous resistance, R
PV
 is pulmonary valve 
resistance, C
PUL
 is pulmonary system compliance, R
PUL
 is pulmonary 
system resistance, and R
TV
 is tricuspid valve resistance.
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over the other stages of the cardiac cycle. Presented in Table II 
alongside SV are the total output results for the LV over a 
single cardiac cycle and the effective EF, which include contri-
butions from the LVAD. Whereas the EF of the LV in the un-
treated acutely failing heart is 28%, the effective EF of the LV 
rises to 34% and then 55% for partial LVAD assistance operating 
at 2.0 L/min to 4.5 L/min, respectively. This was accompanied 
by a reduction of the LV ED volume through LVAD operation 
to within 1.5% of the normal LV ED volume. Additionally, the 
LVAD significantly reduced ED pressure by 10.1-20.8 mmHg 
operating at this range (2.0-4.5 L/min). LVAD operation shifts 
pressures in the LV towards normal ranges over the cardiac cy-
cle, as seen in Table II. The change of function of the RV is sig-
nificantly dependent on the LV. Because the model circulatory 
system is a closed loop with pressures, volumes, and resulting 
flows that depend on the entire system, the RV pump func-
tion will naturally adjust to match the pump function of the LV. 
This is seen in Table II, which shows the SV of the RV matches 
closely with the total output of the LV in all simulated cases. 
Although cavity pressure and volume in the RV are not as sig-
nificantly affected as in the LV, the overall function of the RV 
is still just as severely compromised due to its dependence on 
LV function. This dependence works both ways, as seen in the 
case of LVAD  operation at 4.5 L/min, which brings the effective 
SV and EF for both ventricles within 2% of normal values.
Strain results
Strain profiles of the heart (along the myofiber direc-
tion) at ED are presented in Figure 3. The elevated strains 
 experienced in the heart with ALHF, which lead to adverse 
 remodeling, are clearly decreased by the use of the partial 
LVAD throughout the cardiac cycle. The models with incor-
porated partial LVADs predict a minor reduction of strains 
for LVAD operation of 2 L/min and a significant reduction in 
strains for LVAD operation at 4.5 L/min. Strains are critically 
reduced at ED (Fig. 3), the point in the cardiac cycle which 
would subject the LV to largest strains.
Stress results
Stress distributions for myofiber stress (along the local 
muscle fiber direction) are presented in Figure 4 at ED and 
Figure 5 at ES. The volumetric-averaged myofiber stress 
was calculated at ED and ES and the mean values with stan-
dard deviations are presented in Table III for the RV and LV 
separately. The resulting mean myofiber stress found in the 
healthy LV was 1.47 ± 20.72 kPa at ED, and 14.45 ± 106.72 kPa 
at ES. Impaired LV contractility resulted in an increase of LV 
mean myofiber stress to 7.47 kPa, roughly 5 times the normal 
values at ED. Increases were similar in RV myofiber stress at 
ES. For partial LVAD assistance, myofiber stress was signifi-
cantly reduced in the LV, returning to lower values of 4.00 
and 1.26 kPa for LVAD operation at 2.0 and 4.5 L/min, respec-
tively. This is seen qualitatively in Figure 4, which also shows 
the assisted LV presenting a more ellipsoidal shape at ED 
compared to the heart with ALHF. Myofiber stress distribu-
tions throughout the cardiac cycle for all 4 cases are shown 
in the online-only supplementary video 1 (available online as 
supplementary material at www.artificial-organs.com).
Discussion
The improved LHM allowed us to model the effects of 
varying flow rate on an LVAD connected to a diseased heart 
experiencing ALHF. Using the LHM, and simulating a continu-
ous-flow LVAD between 2.0 and 4.5 L/min, provided a brief in 
silico investigation on the effect partial LVAD may have on the 
TABLE II - Metrics of performance over a cardiac cycle in the normal, acutely failing, and assisted heart
Normal ALHF LVAD 2 L/min LVAD 4.5 L/min ALHF LVAD 2 L/min LVAD 4.5 L/min
Cavity Metric Values % of normal
Le
ft
 V
en
tr
ic
le
EDV (mL) 152.9 206.3 189.8 155.0 135% 124% 101%
EDP (mmHg) 10.7 27.7 17.6 6.9 259% 164% 64%
SV = EDV-ESV (mL) 85.5 57.3 37.5 24.0 67% 44% 28%
Total output (mL) 85.5 57.3 64.4 84.6 67% 75% 99%
EF (incl. LVAD) 56% 28% 34% 55% 50% 61% 98%
maxP (mmHg) 135.1 84.3 85.4 97.4 62% 63% 72%
minP (mmHg) 7.2 19.7 12.5 4.9 274% 174% 68%
Ri
gh
t V
en
tr
ic
le
EDV (mL) 179.9 172.4 175.4 183.0 96% 97% 102%
EDP (mmHg) 3.3 2.7 2.8 3.1 80% 86% 93%
SV = EDV-ESV (mL) 84.6 54.7 66.1 84.8 65% 78% 100%
EF 47% 32% 38% 46% 67% 80% 98%
maxP (mmHg) 28.6 35.1 30.8 26.6 123% 108% 93%
minP (mmHg) 0.4 1.9 2.0 2.2 416% 452% 499%
ALHF = acute left heart failure; LVAD = left ventricular assist device; EDV = end-diastolic volume; ESV = end-systolic volume; EDP = end-diastolic pressure; SV = stroke 
volume; EF = ejection fraction; maxP = maximum ventricular pressure; minP = minimal ventricular pressure.
Partial LV assistance normalizes LV but not RV stress distributions426 
© 2016 The Authors. Published by Wichtig Publishing
Fig. 3 - Long-axis profiles of the 
heart at the end of diastole showing 
contours of logarithmic myofiber 
strain for a normal healthy heart 
(A), a heart experiencing ALHF (B), 
a heart with ALHF and partial LVAD 
running at 2 L/min (C), and a heart 
with ALHF and partial LVAD running 
at 4.5 L/min (D). The deformed pro-
file of the normal healthy heart (A) 
is placed behind profiles of cases (B) 
to (D) as a grey silhouette for com-
parison.
Fig. 4 - Long-axis profiles of the 
heart at the end of diastole show-
ing contours of myofiber stress for 
a normal healthy heart (A), a heart 
experiencing ALHF (B), a heart with 
ALHF and partial LVAD running at 
2 L/min (C), and a heart with ALHF 
and partial LVAD running at 4.5 L/min 
(D). The deformed profile of the 
normal healthy heart (A) is placed 
behind profiles of cases (B) to (D) as 
a grey silhouette for comparison.
acutely failing human heart. Monitoring left and right ventric-
ular mechanics, our study presented clear improvements to 
cardiac function in the acutely failing human heart. This was 
seen in the return to normal values for SVs and EFs in both 
ventricles with LVAD operation at 4.5 L/min. The most dramat-
ic improvement, however, was seen in the reduction of pres-
sure, chamber size and stress in the LV at ED. The  reduction in 
chamber size and LV preload due to LVADs is well established 
in clinical findings (33, 34) and other numerical investigations 
(18, 32, 35).
Mean stress results found in our study for the LV at ED and 
ES match closely to the mean reported values in a recent study 
outlining stress values for healthy human LV cardiac models 
(21). The distribution of stresses is much larger in our model 
because of its more complex geometric representation and 
the use of a more sophisticated material model that includes 
regionally timed activation due to the electro-mechanical 
 coupling (19). Presented alongside Figures 4 and 5 (or the 
online-only supplementary video clip), these values are given 
greater context: the beating heart is not a homogenous entity 
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and experiences a complex combination of compressive and 
tensile stresses throughout the cardiac cycle.
The reduction of wall stress found at ED due to LVAD use 
is critically important. Changes in mechanical loading condi-
tions, particularly ventricular wall stress, are thought to be 
a fundamental trigger for remodeling in the heart (36-38). 
Forces or stresses in the intact heart wall cannot be measured 
directly (39), and although imaging techniques can provide 
accurate strain information from in vivo hearts, this does 
not translate to stress without severe assumptions. For ex-
ample, Laplace’s law, used to estimate average stress across 
the heart wall, makes considerable assumptions with respect 
to the cardiac structure and provides considerably different 
results compared to anatomically accurate finite element 
models (40).
The modest changes to ES stress in the LV due to ALHF 
and subsequent LVAD operation are intriguing. A recent finite 
element study of an isolated LV with reduced contractility and 
LVAD support also reported modest changes in ES stress due 
to LVAD support (35). It is possible that decreased loading of 
the acutely failing LV at ED, which would result in a relatively 
reduced contraction, is offset by the increase in arterial pres-
sure that the LV is working against during ejection, resulting in 
small changes to ES stress. A similar argument could be made 
for the changes from the normal to acutely failing heart.
A physiological improvement in contractility for patients 
with LVADs is likely due to recovery post-unloading, as our 
model shows that the reduction in ED preload does not 
directly improve contractility. This can be clearly seen in 
 Figure 4, whereby only the healthy heart shows that signifi-
cant portions of the LV, beyond papillary muscle, experience 
compressive stress. Although LVAD support reduces the LV 
chamber volume at ED, chamber volume remains inflated 
for the remainder of the cardiac cycle. Our model shows that 
LVAD operation mitigates some of the elevated stresses ex-
perienced in the RV at ES, but the overall mean stress in the 
RV remains high (Tab. III). The elevated stresses sustained 
throughout LVAD support in the RV at ES are likely due to 
the mechanical and structural dependence of the RV on LV 
contractility, which remain impaired despite LVAD operation. 
Fig. 5 - Long-axis profiles of the 
heart at the end of systole show-
ing contours of myofiber stress for 
a normal healthy heart (A), a heart 
experiencing ALHF (B), a heart with 
ALHF and partial LVAD running at 
2 L/min (C), and a heart with ALHF 
and partial LVAD running at 4.5 L/
min (D). The deformed profile of the 
normal healthy heart (A) is placed 
behind profiles of cases (B) to (D) as a 
grey silhouette for comparison.
TABLE III -  ED and ES volumetric-averaged mean stress results for the normal, acutely failing, and assisted heart presented separately for 
the LV and RV
Simulation Normal ALHF LVAD 2 L/min LVAD 4.5 L/min ALHF LVAD 2 L/min LVAD 4.5 L/min
Cavity Metric Values (kPa) % of normal
LV ED 1.47 ± 20.72 7.47 ± 35.7 4 ± 29.12 1.26 ± 19.59 508% 272% 85%
ES 14.45 ± 106.72 16.39 ± 56.81 16.6 ± 56.92 15.81 ± 54.23 113% 115% 109%
RV ED 1.7 ± 18.06 1.59 ± 16.38 1.6 ± 16.73 1.62 ± 17.47 94% 94% 95%
ES 1.51 ± 81.78 8.63 ± 74.01 6.89 ± 74.19 5.18 ± 71.52 570% 455% 342%
Results are presented with standard deviations.
ALHF = acute left heart failure; LVAD = left ventricular assist device; ED = end-diastole; ES = end-systole.
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Since the active contraction law in our model includes length-
dependent activation, the resulting contractile force within 
the LV decreases with LVAD operation – as strain reduction is 
a primary outcome of LVAD operation. This is seen in Figure 5, 
where the unassisted heart with ALHF displays increased wall 
thickness at ES compared to the assisted hearts with ALHF. 
It is likely that the functional improvements made to the RV 
through the introduction of the LVAD are partially offset by 
negative secondary outcomes on the RV. This is in line with 
clinical findings, which report positive (41), neutral (42) and 
negative outcomes (43, 44) on RV function through LVAD use. 
However, reports of RV failure occurring in 10%-30% of pa-
tients treated with LVADs (43-47) – depending on the sever-
ity of RV failure, the characteristics of the study population, 
and the type of LVAD – suggests that the balance between 
positive and negative outcomes on the RV is often missed. 
Although our simulated results showed that stresses in the 
LV were normalized through LVAD use, RV stresses were not 
as easily recovered. The quantification and monitoring of RV 
stress may play a critical role in optimizing LVAD treatment to 
avoid RV dysfunction.
This is the fourth study utilizing the LHM and the first to 
include length-dependent activation in simulating the con-
tractile behavior of the heart in systole. To the best of our 
knowledge, this is also the first computational LVAD study 
that utilizes a 4-chamber anatomical description of the heart. 
This allowed us to capture the mechanical changes in the ven-
tricles due to reduced LV contractility with and without as-
sistance. The return to normal values for SVs and EFs in both 
ventricles supports the position that partial LVADs may pro-
vide significant benefit for patients with ALHF (12, 32). This 
position was further supported by a strain and stress analysis, 
showing the reduction of stress in the LV and a qualitative 
return to shape through the influence of partial LVADs.
The ability to accurately account for and predict chang-
es to the myofiber stress in the heart could significantly aid 
clinical decision making and therapy optimization for patients 
undergoing LVAD treatment, whereby stress-driven adverse 
remodeling could be mitigated or even reversed (48). Realis-
tic, physics-based computational modeling offers a potential 
means to tailor treatments in a patient-specific framework. 
The modeling presented in this study could be advanced by 
including patient-specific data and utilized in clinical decision-
making for patients who may benefit from partial, instead of 
full, LV support.
Although the LHM exemplifies state-of-the-art model-
ing techniques in cardiovascular computational modeling, 
 limitations still apply (22). The functional improvements seen 
in the LHM model with ALHF treated with a partial LVAD are 
in part facilitated by the idealized in silico description of car-
diac tissue, modeled here as purely elastic, and as such, the 
changes in deformation between healthy and ALHF are in-
herently more recoverable than such changes would be in a 
chronically remodeled failing heart. Here, the heart topology 
was unaltered from the normal heart and ALHF was induced 
by lowering the contractility in the LV only. In this sense, ad-
verse remodeling due to chronic LHF and reverse  remodeling 
due to the partial LVAD were neglected. The model can be im-
proved by enriching the kinematic and constitutive models to 
include growth modeling to account for chronic  remodeling 
and reverse remodeling phenomena (49). Future improve-
ments to coupled fluid-structure interactions and patient-
specific features would provide a broader and increasingly 
reliable set of model predictions. Furthermore, our simulated 
LVAD flow was created using unchanging constant flow speci-
fications, whereas real-life LVADs perform according to mo-
tor function and pressure gradients. As such, our simulated 
LVAD flow is insensitive to mean arterial pressure (afterload), 
which would induce fluctuations in flow-rate performance. 
A description of LVAD flow rate sensitive to afterload would 
also provide another level of sophistication to the model.
In conclusion, our study advanced the systolic material 
description of the Dassault Systèmes LHM to include length-
dependent activation. We used this improved LHM to simu-
late ALHF through the overall reduction in contractility of the 
LV and simulated the use of a partial-support LVAD on that 
heart. Our simulations strongly suggest that an LVAD is effec-
tive in normalizing LV stresses but not RV stresses that be-
come elevated as a result of ALHF.
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